Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313144

— · D

75474109-3a27-525d-abe3-993e6afd6efb

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.670
  • ALLOGRAFT_REJECTION+0.600
  • INTERFERON_GAMMA_RESPONSE+0.600
  • E2F_TARGETS+0.580
  • G2M_CHECKPOINT+0.480
  • MYC_TARGETS_V1+0.400
  • IL6_JAK_STAT3_SIGNALING+0.300
  • MTORC1_SIGNALING+0.280
  • COMPLEMENT+0.260
  • INFLAMMATORY_RESPONSE+0.210

Top 10 suppressed

  • ANGIOGENESIS-0.550
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
  • NOTCH_SIGNALING-0.340
  • UV_RESPONSE_DN-0.330
  • ESTROGEN_RESPONSE_EARLY-0.320
  • WNT_BETA_CATENIN_SIGNALING-0.320
  • COAGULATION-0.310
  • MYOGENESIS-0.310
  • XENOBIOTIC_METABOLISM-0.280
  • HYPOXIA-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BSR_11_0107_E3_S77
breast-umap@18
—D0.900
2TCGA-BH-A209-01A-11R-A157-07
breast-umap@18
—D0.895
3TCGA-C8-A1HM-01A-12R-A137-07
breast-umap@18
—C0.890
4MBCProject_1542_T2_RNA
breast-umap@18
—D0.886
5SRR8518291
breast-umap@18
—D0.882
6TCGA-E2-A1II-01A-11R-A144-07
breast-umap@18
—E0.881
7SRR8518185
breast-umap@18
—D0.879
8SRR25043627
head-neck@1
——0.874
9BDCM_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
ccle-aml@v2024.1
AML—0.869
10MBCProject_5971_T1_RNA
breast-umap@18
—D0.868

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.670Inavolisib— uncovered
ALLOGRAFT_REJECTION0.600Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.600Idelalisib— uncovered
E2F_TARGETS0.580Inavolisib— uncovered
G2M_CHECKPOINT0.480Inavolisib— uncovered
MYC_TARGETS_V10.400Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.300Inavolisib— uncovered
MTORC1_SIGNALING0.280Inavolisib— uncovered
COMPLEMENT0.260Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.210Idelalisib— uncovered
KRAS_SIGNALING_DN0.210Remibrutinib— uncovered
SPERMATOGENESIS0.210Inavolisib— uncovered
IL2_STAT5_SIGNALING0.200Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.180Remibrutinib— uncovered
KRAS_SIGNALING_UP0.170Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.150Idelalisib— uncovered
DNA_REPAIR0.140Idelalisib— uncovered
MITOTIC_SPINDLE0.130Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.120Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.100Inavolisib— uncovered